rolapitant

FDA Drug Profile — Varubi

Drug Details

Generic Name
rolapitant
Brand Names
Varubi
Application Number
NDA206500
Sponsor
TerSera Therapeutics LLC
NDC Codes
1
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
ROLAPITANT HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )